{
    "clinical_study": {
        "@rank": "33652", 
        "acronym": "CPVsSPCI", 
        "arm_group": [
            {
                "arm_group_label": "complete revascularization group", 
                "description": "this group underwent second PCI procedure on the non-culprit vessels and reveived 100-120 IU/kg unfractionated heparin during PPCI, followed by 3 days administration of low molecular weight heparin or Fondaparinux sodium after procedure. Patients in the CP group and CR group after second PCI procedure were given conservative medicine such as Statins which were not contraindicated to the patients."
            }, 
            {
                "arm_group_label": "conservative pharmacotherapy group", 
                "description": "patients in conservative group undergoing pharmacotherapy after PPCI. The drugs were the same between two groups."
            }
        ], 
        "brief_summary": {
            "textblock": "To compare the different effect of conservative pharmacotherapy and Staged Percutaneous\n      Coronary Intervention (SPCI) on significant non-culprit lesions in patients with ST-segment\n      elevation myocardial infarction (STEMI) at presentation remains controversial"
        }, 
        "brief_title": "Non-culprit Vessels for ST-Segment Elevation Myocardial Infarction", 
        "condition": [
            "Conservative Pharmacotherapy", 
            "Staged Percutaneous Coronary Intervention", 
            "Non-culprit Vessels", 
            "ST-Segment Elevation Myocardial Infarction"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Infarction", 
                "Myocardial Infarction"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  age 18 to 75 with continuous ischemic chest pain for \u2265 30 minutes and ST-segment of\n             electrocardiographic leads between V2 and V3 elevated \u2265 0.2 mV (or \u2265 0.1 mV in \u2265 2\n             other continuous electrocardiographic leads), cardiac troponin I (cTn I) elevation of\n             > 0.05 ng/ml, coronary arteriography within 12 hours after the onset of symptoms\n             indicating lesion in culprit vessel with thrombolysis in myocardial infarction (TIMI)\n             flow grade 0 to 1, merely underwent PPCI. Additionally, coronary arteriography\n             corroborates lesions in non-culprit vessel (Besides the culprit vessel, there are \u2265\n             70% stenoses in one or more coronary vessels in which diameters were \u2265 2 mm).\n\n        Exclusion Criteria:\n\n          -  left main coronary artery disease, cardiogenic shock, complete left bundle branch\n             block (CLBBB) PPCI treated culprit and non-culprit vessels, PPCI failure patients\n             with postsurgical haemodynamic instability or spontaneous ischemia, \u2265 70% stenoses of\n             vessels remained during the hospitalization after staged PCI, history of PCI or\n             Coronary Artery Bypass Grafting (CABG), history of chronic cardiac failure, bleeding\n             diathesis, prior administration of thrombolytic therapy, known thrombopenia or\n             leucopenia, sever liver and kidney dysfunction, active infection, immune system and\n             connective tissue diseases, known contraindications to aspirin or heparin, life\n             expectancy < 1 year, had major procedure within 3 months, uncontrolled hypertension,\n             ischemic stroke within 30 days, hemorrhagic stroke, intracranial diseases including\n             and arteriovenous malformation, extensive traumatic cerebral infarction within 6\n             weeks, oral anticoagulant therapy, severe myocardial infarction related complications\n             and perioperative death"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "STEMI patients after culprit vessels treated by PPCI"
            }
        }, 
        "enrollment": {
            "#text": "306", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 31, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02154919", 
            "org_study_id": "CPVsSPCI"
        }, 
        "intervention": {
            "arm_group_label": "complete revascularization group", 
            "intervention_name": "Percutaneous coronary intervention", 
            "intervention_type": "Procedure"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 31, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China", 
                    "state": "Beijing", 
                    "zip": "100038"
                }, 
                "name": "Beijing Shijitan Hospital"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_groups": "2", 
        "official_title": "Conservative Pharmacotherapy Versus Staged Percutaneous Coronary Intervention on Non-culprit Vessels for ST-Segment Elevation Myocardial Infarction Patients With Multivessel Disease", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "China: Beijing Municipal Science and Technology Commission"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Major Adverse Cardiovascular Events", 
            "safety_issue": "Yes", 
            "time_frame": "360days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02154919"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Beijing Shijitan Hospital", 
            "investigator_full_name": "Peng Jian Jun", 
            "investigator_title": "Beijing Shijitan Hospital, Capital Medical University , Beijing, China", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Beijing Shijitan Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Beijing Shijitan Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2011", 
        "study_design": "Observational Model: Case Control, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}